Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Meike Kaulfuss"'
Autor:
Lukas Egli, Meike Kaulfuss, Juliane Mietz, Arianna Picozzi, Els Verhoeyen, Christian Münz, Obinna Chijioke
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-18 (2024)
Abstract Background CAR NK cells as vehicles for engineered “off-the-shelf” cellular cancer immunotherapy have attracted significant interest. Nonetheless, a comprehensive comparative assessment of the anticancer activity of CAR T cells and CAR N
Externí odkaz:
https://doaj.org/article/8f50899e7813436a9d318bb05e27875d
Publikováno v:
EBioMedicine, Vol 106, Iss , Pp 105240- (2024)
Summary: Background: Humanized tumour models could be particularly valuable for cancer immunotherapy research, as they may better reflect human-specific aspects of the interfaces between tumour and immune system of human cancer. However, endogenous a
Externí odkaz:
https://doaj.org/article/97362e817bc54a9186814285396df9bd
Autor:
Meike Kaulfuss, Juliane Mietz, Astrid Fabri, Johannes vom Berg, Christian Münz, Obinna Chijioke
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Human natural killer (NK) cells are cytotoxic effector cells that are increasingly harnessed in cancer immunotherapy. NKG2A/CD94 is an inhibitory receptor on NK cells that has established regulatory functions in the direct interaction with t
Externí odkaz:
https://doaj.org/article/70f5ce4c167d444a94c9bb1b31270e67
Autor:
Patrick C. Freitag, Meike Kaulfuss, Lea Flühler, Juliane Mietz, Fabian Weiss, Dominik Brücher, Jonas Kolibius, K. Patricia Hartmann, Sheena N. Smith, Christian Münz, Obinna Chijioke, Andreas Plückthun
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 29, Iss , Pp 120-132 (2023)
Clinical success in T cell therapy has stimulated widespread efforts to increase safety and potency and to extend this technology to solid tumors. Yet progress in cell therapy remains restricted by the limited payload capacity, specificity of target
Externí odkaz:
https://doaj.org/article/add16acf3bd84d4ca22dbca9f3182210
Autor:
Maxim Cherneha, Johannes Korth, Meike Kaulfuß, Mirko Trilling, Marek Widera, Hana Rohn, Sebastian Dolff, Nina Babel, André Hoerning, Andreas Kribben, Oliver Witzke
Publikováno v:
Viruses, Vol 13, Iss 3, p 424 (2021)
Reactivations of BK polyoma virus (BKPyV) and human cytomegalovirus (HCMV) frequently cause life- and graft-threatening complications after renal transplantation. Both viruses are dependent on the mTOR pathway for replication. In this study we invest
Externí odkaz:
https://doaj.org/article/85483e483f1449148439e2a285188ce6
Autor:
Julien Lazarovici, Tarik Azzi, Philippe Busson, Christian Münz, Elena Pánisová, Juliane Mietz, Monika Kotur, David Ghez, Meike Kaulfuss, Simone Bürgler, Obinna Chijioke, Alina Danu, Christoph Berger, Anna Lünemann
Publikováno v:
Cancer Immunology, Immunotherapy
Cancer Immunology, Immunotherapy, Springer Verlag, In press, ⟨10.1007/s00262-021-02956-x⟩
Cancer Immunology, Immunotherapy, Springer Verlag, In press, ⟨10.1007/s00262-021-02956-x⟩
Around 30–50% of classical Hodgkin lymphoma (cHL) cases in immunocompetent individuals from industrialized countries are associated with the B-lymphotropic Epstein-Barr virus (EBV). Although natural killer (NK) cells exhibit anti-viral and anti-tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bba43afb9ad71aaa047802acd8304f20
https://www.zora.uzh.ch/id/eprint/213873/
https://www.zora.uzh.ch/id/eprint/213873/
Publikováno v:
Der Nephrologe. 13:161-166
Die Etablierung der Nierentransplantation als beste verfugbare therapeutische Option fur Patienten mit terminaler Niereninsuffizienz fuhrte zu einer enormen Verbesserung des Uberlebens und der Lebensqualitat der Patienten. Der Preis einer erfolgreich
Autor:
Ulrich Vogel, Meike Kaulfuß, Oliver Witzke, Hana Rohn, Heike Claus, Thorsten Feldkamp, Andreas Kribben, Anja Gäckler
Publikováno v:
Nephrology Dialysis Transplantation.
Background The C5 complement inhibitor eculizumab is a first-line treatment in atypical haemolytic uraemic syndrome (aHUS). Therapy with eculizumab is associated with a highly increased risk for meningococcal infection. Therefore, vaccination is high
Autor:
Egli, Lukas1 (AUTHOR), Kaulfuss, Meike1 (AUTHOR), Mietz, Juliane1 (AUTHOR), Picozzi, Arianna1 (AUTHOR), Verhoeyen, Els2,3 (AUTHOR), Münz, Christian4 (AUTHOR), Chijioke, Obinna1,5 (AUTHOR) chijioke@immunology.uzh.ch
Publikováno v:
Experimental Hematology & Oncology. 5/14/2024, Vol. 13 Issue 1, p1-18. 18p.